Abstract
Hallucinogenic substances extend back into pre-history as religious sacraments, as shamanic medicines, and as part of some tribal rituals, but the reader is likely most familiar with their recreational, illicit use. Since the most potent hallucinogen, lysergic acid diethylamide, “escaped” the research laboratory and fueled, starting in the 1960s, a popular movement of awareness about the potentials for hallucinogen intoxication, “modern” societies have resisted their acceptance. Despite prohibition, some 35 million Americans are estimated to have tried a hallucinogen at least once in their lifetime and approximately 4 million are active users (at least one use in a year); yet less than 17,000 emergency room visits per year are associated with hallucinogen use. This chapter reviews basic pharmacology, including psychological and physiological effects, and then presents the most common hallucinogen use disorders (with assessment, differential diagnosis, and treatment options) that are likely to be encountered by medical and allied health care providers. The chapter concludes with a brief update on research suggesting that hallucinogens may assist in recovery from other substance abuse and dependence, and a caution for current research to avoid the methodological flaws and excesses that took place some 40–50 years ago.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham HD (1983) Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 40:884–889
Abraham HD, Mamen A (1996) LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 16:228–231
Abraham HD, McCann UD, Ricaurte GA (2002) Psychedelic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, pp 1545–1556
Abramson HA (ed) (1967) The use of psychotherapy and alcoholism. Bobbs Merrill, Indianapolis, Kansas City, New York
Abuzzahab FS, Anderson BJ (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 6:223–235
Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J (1999) Treatment of acute opioid withdrawal with ibogaine. Am J Addict 8:234–242
American Psychiatric Association (2000) Diagnostic criteria from DSM-IV-TR. American Psychiatric, Washington DC
Anonymous (1966) LSD: the search for definite conclusions. JAMA 196:32–33
Baggott MJ, Erowid E, Erowid F, Robertson LC (2006) Prevalence of chronic flashbacks in hallucinogen users: a web-based questionnaire [Abstract]. Presented at the 68th Annual Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ, 21 June 2006
Boyer EW (2004) Dextromethorphan abuse. Ped Emerg Care 20: 858–963
Cohen S (1960) Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 130:30–40
Doering-Silveira E, Grob CS, de Rios MD, Lopez E, Alonso LK, Tacla C, Da Silveira DX (2005) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 37:141–144
Dribben B, Wood A (2006) Toxicity, hallucinogens—LSD. eMedicine article topic #2809. http://www.emedicine.com
El-Mallakh RS, Halpern JH, Abraham HD (2008) Substance abuse: hallucinogen- and MDMA-related disorders (chapter 60). In: Tasman A, Maj M, First MB, Kay J, Lieberman JA (eds) Psychiatry, 3rd edn. Wiley, London, pp 1100–1126
Fasano A, Barra A, Nicosia P, Rinaldi F, Bria P, Bentivoglio AR, Tonioni R (2008) Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend 96:178–182
Fiorella D, Helsley S, Lorrain DS, Rabin RA, Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology (Berl.) 121:364–372
Frosch WA, Robbins ER, Stern M (1965) Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization. NEJM 273:1245–1239
Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23:388–395
Giannini AJ, Loiselle RH, Giannini MC, Price WA (1987) Phencyclidine and the dissociatives. Psychiatry Med 3:197–217
Giannini AJ, Loiselle RH, Price WA (1984) Antidotal strategies in phencyclidine intoxication. Int J Psychiatry Med 4:513–518
González-Maeso J, Sealfon S (2006) Hormone signaling via G protein-coupled receptors. In: DeGoot LC, Jameson JL (eds) Endocrinology. Elsevier, Amsterdam, pp 177–203
González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836–8843
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Büll U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. Neuropsychopharmacology 20:565–581
Grinspoon L, Bakalar JB (1997) Psychedelic drugs reconsidered, 2nd edn. The Lindesmith Center, New York
Grob CS (1994) Psychiatric research with hallucinogens: what have we learned? Yearbook Ethnomedicine Consciousness Res 3:91–112
Grob CS, McKenna DJ, Callaway CJ, Brito GS, Neves ES, Oberlaender G, Saide OL, Labigalini E, Tacla C, Miranda CT, Strassman RJ, Boone KB (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184:86–94
Grof S (1975) Realms of the human unconsciousness. Viking, New York
Grof S, Goodman LE, Richards WA, Kurland AA (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8:129–144
Halpern JH (2000) Hallucinogens, anesthetic agents, and amphetamines. Pharmaceutical News 7:21–29
Halpern JH (2003) Hallucinogens: an update. Curr Psychiatry Rep 5:347–354
Halpern JH (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131–138
Halpern JH (2007) Hallucinogens in the treatment of alcoholism and other addictions. In: Winkelman M, Roberts T (eds) Psychedelic medicine: scientific evidence for hallucinogenic substances as treatments, vol 2. Praeger, Westport, CT and London, pp 1–14
Halpern JH, Pope HG Jr (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53:247–256
Halpern JH, Pope HG Jr (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 69:109–119
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58:624–631
Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ (2008) Evidence of health and safety in American Members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14:SR15–SR22
Hoffer A, Osmond H (1966) New hope for alcoholics. University Books, New Hyde Park, NY
Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976–991
Hintzen A, Passie T (2010) The pharmacology of LSD. Oxford University Press, Oxford, New York
Holland D (2004) Flashback-Phänomene als Nachwirkung von Halluzinogeneinnahme. Hannover: Hannover Medical School Dissertation
Hillebrand J, Olszewksi D, Sedefov R (2006) Hallucinogenic mushrooms: an emerging trend case study. European Monitoring Centre for Drugs and Drug Addiction, Lisbon
Hollister LE (1984) Effects of hallucinogens in humans. In: Jacobs BL (ed) Hallucinogens: neurochemical, behavioral, and clinical perspectives. Raven, New York, pp 19–33
Johnston LD, Bachman JG, O’Malley PM (2006) Monitoring the Future: questionnaire responses from the nation’s high school seniors, 2005. Institute for Social Research, Ann Arbor, MI
Kurland AA, Savage C, Pahnke WN, Grof S, Olsson JE (1971) LSD in the treatment of alcoholics. Pharmakopsychiatrie Neuro-Psychopharmakologie 4:83–94
Leuner H (1962) Die experimentelle psychose. Julius Springer, Berlin, Heidelberg
Lotsof HS (1985) Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent # 4,499,096
Markel H, Lee A, Holmes RD, Domino EF (1994) LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 125: 817–819
Malleson N (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 118:229–230
Mash DC, Kovera CA, Buch BE, Norenberg MD, Shapshak P, Hearn WL, Sanchz J (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann NY Acad Sci 844: 274–292
Morehead DB (1997) Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol 17:327–328
Mottin JL (1973) Drug-induced attenuation of alcohol consumption: a review and evaluation of claimed, potential or current therapies. Q J Stud Alcohol 34:444–472
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369: 1047–1063
O’Brien CP (2005) Drug addiction and drug abuse. In: Brunton L, Lazo J, Parker K (eds) Goodman & Gillman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 607–628
Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann NY Acad Sci 66:418–434
Passie T (1997) Psycholytic and psychedelic therapy research: a complete international bibliography 1931–1995. Laurentius, Hannover
Pletscher A, Ladewig D (eds) (1994) 50 Years of LSD: current status and perspectives of hallucinogens. Parthenon, New York & London
Riba J, Romero S, Grasa E, Mena E, Carrio I, Barbanoj MJ (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl.) 186:93–98
Roth, BL, Willins DL, Kristiansen K, Kroeze WK (1998) 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 79:231–257
SAMHSA, Office of Applied Studies (2007) Results from the 2006 national survey on drug use and health: national findings. NSDUH Series H-32, DHHS Publication No. SMA 07–4293, Rockville, MD
SAMHSA, Office of Applied Studies (2007) Drug abuse warning network, 2005: national estimates of drug-related emergency department visits. DAWN Series D-29, DHHS Publication No. SMA 07-4256, Rockville, MD
Savage C, McCabe OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict. Arch Gen Psychiatry 28:808–814
Schultes RE, Hofmann A, Rätsch C (2001) Plants of the gods: their sacred, healing and hallucinogenic powers, 2nd edn. Inner Traditions, Vermont
Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146:174–186
Strassman RJ (1984) Adverse reactions for psychedelic drugs: a review of the literature. J Nerv Ment Dis 172:577–595
Strassman RJ (1995) Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects. J Nerv Ment Dis 183:127–138
Tacke U, Ebert MH (2005) Hallucinogens and phencyclidine. In: Kranzler HR, Ciraulo DA (eds) Clinical manual of addiction psychopharmacology. American Psychiatric, Washington, DC, pp 211–241
Taylor RL, Maurer JI, Tinklenberg JR (1970) Management of “bad trips” in an evolving drug scene. JAMA 213:422–425
Ungerleider JT, Pechnick, RN (1999) Hallucinogens. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment. American Psychiatric, Washington, DC, pp 195–203
Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialog Clin Neurosci 3:265–279
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357–372
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897–3902
Wasson RG (1961) The hallucinogenic fungi of Mexico: an inquiry into the origins of the religious idea among primitive peoples. Bot Mus Leaflets Harv Univ 19:137–162
Wright D, Sathe N, Spagnola K (2007) State estimates of substance use from the 2004–2005 national surveys on drug use and health (DHHS Publication No. SMA 07-4235, NSDUH Series H-31). Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD
Zinberg NE (1986) Drug, set, and setting: the basis for controlled intoxicant use. Yale University, New Haven, CT
Acknowledgments
The authors greatly appreciate the editing assistance of medical student Sean Doherty of Cardiff University School of Medicine.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Halpern, J.H., Suzuki, J., Huertas, P.E., Passie, T. (2010). Hallucinogens. In: Johnson, B. (eds) Addiction Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0338-9_54
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0338-9_54
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0337-2
Online ISBN: 978-1-4419-0338-9
eBook Packages: MedicineMedicine (R0)